Yaupon Completes Patient Enrollment For Phase-II Study Of Clearazide

Yaupon has completed enrollment for a pivotal phase-II clinical trial for Clearazide, for the treatment of early-stage cutaneous T-cell lymphoma (CTCL – stages 1-2a). The randomized, double-blind, controlled clinical study involves patients with cutaneous T-cell lymphoma.

The study, which is being conducted under a Special Protocol Assessment with the FDA, has enrolled 260 patients in 13 cancer centers in the US. The company is expecting to complete treatment in the study by June of 2010.

Robert Alonso, CEO of Yaupon, said: Cutaneous T-cell lymphoma, like all cancers, is a terrible burden on families worldwide. Completion of patient enrollment in this landmark study is a major milestone in our efforts to advance Clearazide through regulatory approval and to help patients with CTCL. We look forward to completing this study and filing our NDA next year,